Nasdaq
$67.42▼ 0.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.15BShares out 1.800M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
61- 2d agoPre-market26.10.23 22:008-KKey event#●●●#●●●
Tempus AI, Inc.Bullish
Tempus AI has entered into agreements with Bristol-Myers Squibb (BMS) and Pathos AI to provide data licensing and analytical tools. These contracts will generate a total of $192.5 million in cash payments over approximately five years, expanding the company's reach in oncology and neurology data.…more
$67.42-0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoPre-market26.10.22 13:15filedEFFECTOther
Tempus AI, Inc.
Tempus AI, Inc. received effectiveness approval from the SEC for its registration statement on October 21, 2026. This authorization allows the company to proceed with the issuance and sale of the registered securities.…more
$67.42-0.30%vs prev closeView filingShare - 3d agoAfter-hours26.10.22 05:20424B3Offering
Tempus AI, Inc.
Tempus AI has entered into a definitive merger agreement to acquire Personalis, with a special meeting of Personalis stockholders scheduled for November 30, 2026. Personalis stockholders will receive Tempus Class A common stock as consideration, with a potential cash election of $16.25 per share under certain conditions. Merck and Tempus, holding approximately 13% and 12% of voting power respectively, have agreed to vote in favor of the merger.…more
$67.42-0.30%vs prev closeView filingShare
60 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 22:11#●●●#●●●#●●●
Tempus AI Expands Strategic AI and Data Partnership with BMS
Tempus AI has entered a multiyear agreement to license its multimodal oncology data and AI platform to Bristol Myers Squibb through 2031. Additionally, both companies are collaborating with Pathos AI to develop specialized datasets and AI capabilities for neurological disease research.…more
$67.42-0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 6d agoPre-market26.10.19 21:37
●●●●●●●● ●●●●● ●●●●●●
Tempus AI announced study results at the ESMO Congress showing its AI-enabled pre-screening panel for lung cancer achieved over 80% sensitivity across 12 biomarkers. While the technology aims to improve diagnostic efficiency and patient access to therapy, it remains in the development phase as a supplementary tool.…more
$67.42-0.30%vs prev closeShareBenzinga - 10.7Regular26.10.08 02:44
●●●●●●●● ●●●●● ●●●●●●
Tempus AI has expanded its partnership with Moderna and Merck to support the commercialization of individualized neoantigen therapies through NGS services. As the financial terms of the collaboration were not disclosed, the market impact remains neutral.…more
$67.42-0.30%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report